Komori
Presentation materials for financial results2931Euglena Co.,Ltd.Food

Q1 FY2026 December Results Briefing

In Q1 FY2026 December, revenue and all profit figures exceeded the year-earlier period, driven by growth in the Healthcare business. Although advertising investment was increased, adjusted EBITDA and operating profit continued to grow, while the net loss narrowed substantially.

Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1262
¥ million (year-on-year increase in revenue)
Wording
Conditional
How definitive the wording is.

Contents of this document

Presentation materials for financial resultsFirst quarter of the fiscal year ending December 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥13,197 million+11.0%
Operating profit¥837 million+35.0%
Ordinary income¥782 million+80.0%
Net income¥-32 million
Gross Profit Margin68 %
Operating profit margin6.3 %
Selling, general and administrative expenses¥8,156 million
Results for the three months of the current quarter
Consolidated
Net Sales
¥13,197 million
Operating profit
¥837 million
Ordinary income
¥782 million
Net income
¥-32 million
Adjusted EBITDA
¥1,822 million
Full-year earnings forecast
Net Sales
¥52,000 million
Adjusted EBITDA
¥7,000 million
Operating profit
¥3,200 million
Ordinary income
¥2,800 million
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales25
Adjusted EBITDA26
Operating profit26
Ordinary income28
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progressing slightly ahead of plan and the earnings forecast
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Year-on-year change in adjusted EBITDA
FY2025Q1
¥1,546 million
Euglena Healthcare
¥-92 million
Epora
¥-40 million
MEJ
¥-25 million
Q'SAI
¥318 million
Satis Pharma
¥131 million
Other Healthcare
¥-23 million
Biofuels
¥-20 million
Other
¥14 million
Corporate Expenses
¥14 million
FY2026Q1
¥1,822 million
Adjusted EBITDA by line item
Gross profit
¥657 million
Advertising expenses
¥-378 million
Other selling expenses
¥-72 million
Personnel Expenses
¥-87 million
Administrative expenses
¥0 million
Research and development costs
¥13 million
Grant
¥75 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Advertising investment is expected to increase from Q2 onward. Uncertainty surrounding the situation in the Middle East has been taken into account. Numerical assumptions: Not disclosed.
New initiatives
  • Acquisition of the Golden Euglena business
  • Development and launch of alternative products, and raw-material sales and OEM supply of EOD-1 powder
  • Joint research and patent application with Satis Pharma on ultra-long-chain ceramides
  • Mass production and quality validation of genome-edited Euglena for food applications
  • Introduction of Susteo 51 into Tokyu Bus's regular operations
Key KPIsA metric the company considers important as a management benchmark.
  • Number of group direct-to-consumer subscription customers71 More than 10,000 people
    Year on year against the same period last yearIncreased
  • Number of subscription customers for products targeting families with children1 More than 10,000 people
    Year on year against the same period last yearApproximately tripled over the past 6 months
  • Number of existing route buses equipped with Susteo 51 renewable fuel65 Units
  • Global energy-transition investment2.3 USD trillions
    Year on year against the same period last year+8.0%
Segment results
Healthcare Business
Net Sales
¥12,189 million+12.0%
Adjusted EBITDA
¥2,301 million+13.0%
Biofuels business
Net Sales
¥256 million-32.0%
Adjusted EBITDA
¥-72 million
Other Businesses
Net Sales
¥757 million+59.0%
Adjusted EBITDA
¥-65 million
Consolidated total
Net Sales
¥13,197 million+11.0%
Adjusted EBITDA
¥1,822 million+18.0%
Market Size / Share
  • Global energy-transition investment in 20252.3 USD trillions
    Year on year against the same period last year+8.0%
  • Joint venture interest in the Malaysian commercial plant15 %
  • Annual volume handled by the Malaysian commercial plant10 10,000 kL/year
Contents of this document
ItemDetails
Document typePresentation materials for financial results
Fiscal Period CoveredFirst quarter of the fiscal year ending December 2026
Net Sales¥13,197 million (YoY +11.0%)
Operating profit¥837 million (YoY +35.0%)
Ordinary income¥782 million (YoY +80.0%)
Net income¥-32 million
Gross Profit Margin68 %
Operating profit margin6.3 %
Selling, general and administrative expenses¥8,156 million
Results for the three months of the current quarterConsolidated Net Sales ¥13,197 million / Operating profit ¥837 million / Ordinary income ¥782 million / Net income ¥-32 million / Adjusted EBITDA ¥1,822 million
Full-year earnings forecastNet Sales ¥52,000 million / Adjusted EBITDA ¥7,000 million / Operating profit ¥3,200 million / Ordinary income ¥2,800 million / Net income Not disclosed
Progress against full-year forecastNet Sales 25 / Adjusted EBITDA 26 / Operating profit 26 / Ordinary income 28
Self-assessment against the planProgressing slightly ahead of plan and the earnings forecast
Segment resultsHealthcare Business Net Sales ¥12,189 million (YoY +12.0%) / Adjusted EBITDA ¥2,301 million (YoY +13.0%) / Biofuels business Net Sales ¥256 million (YoY -32.0%) / Adjusted EBITDA ¥-72 million / Other Businesses Net Sales ¥757 million (YoY +59.0%) / Adjusted EBITDA ¥-65 million / Consolidated total Net Sales ¥13,197 million (YoY +11.0%) / Adjusted EBITDA ¥1,822 million (YoY +18.0%)
Breakdown of Factors Affecting the ChangeYear-on-year change in adjusted EBITDA FY2025Q1 ¥1,546 million / Euglena Healthcare ¥-92 million / Epora ¥-40 million / MEJ ¥-25 million / Q'SAI ¥318 million / Satis Pharma ¥131 million / Other Healthcare ¥-23 million / Biofuels ¥-20 million / Other ¥14 million / Corporate Expenses ¥14 million / FY2026Q1 ¥1,822 million / Adjusted EBITDA by line item Gross profit ¥657 million / Advertising expenses ¥-378 million / Other selling expenses ¥-72 million / Personnel Expenses ¥-87 million / Administrative expenses ¥0 million / Research and development costs ¥13 million / Grant ¥75 million
Key KPIsIndicator name Number of group direct-to-consumer subscription customers / Value 71 More than 10,000 people / Year on year against the same period last year Increased, Indicator name Number of subscription customers for products targeting families with children / Value 1 More than 10,000 people / Year on year against the same period last year Approximately tripled over the past 6 months, Indicator name Number of existing route buses equipped with Susteo 51 renewable fuel / Value 65 Units / Year on year against the same period last year Not disclosed, Indicator name Global energy-transition investment / Value 2.3 USD trillions / Year on year against the same period last year 8 USD trillions
Assumptions Underlying the Business OutlookAdvertising investment is expected to increase from Q2 onward. Uncertainty surrounding the situation in the Middle East has been taken into account. Numerical assumptions: Not disclosed.
Market Size / ShareIndicator name Global energy-transition investment in 2025 / Value 2.3 USD trillions / Year on year against the same period last year 8 USD trillions, Indicator name Joint venture interest in the Malaysian commercial plant / Value 15 %, Indicator name Annual volume handled by the Malaysian commercial plant / Value 10 10,000 kL/year
New initiativesAcquisition of the Golden Euglena business, Development and launch of alternative products, and raw-material sales and OEM supply of EOD-1 powder, Joint research and patent application with Satis Pharma on ultra-long-chain ceramides, Mass production and quality validation of genome-edited Euglena for food applications, Introduction of Susteo 51 into Tokyu Bus's regular operations
Items this document does not state (12)
Unit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Growth in direct-to-consumer and OEM sales in Healthcare, along with increased sales at Satis Pharma and Q'SAI, were the main drivers of the increase in revenue and profit. Although advertising investment was increased, the effect of higher sales more than offset it. The full-year forecast was left unchanged in light of plans to increase advertising investment from Q2 onward and uncertainty surrounding the situation in the Middle East.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Q1 FY2026 December Results Briefing | Euglena Co.,Ltd. (2931) timely disclosure | Komori